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CLINICAL USE OF FOSFOMYCIN CAPSULE
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  1） iT，iosfomycin was administered to 20 patients with chronic urinary tract infection caused by
Pseudomonas or Serratia． Clinical effectiveness was remarkable in 6， good in 9， uncertain in 1， and
none ip 4． Effectiveness rate was thus calculated as 78．950／o．
  2） rvllC for Pseudomonas was 3．13 to 12．5 micrograms／ml in 6 of 7 cases， which was superior to
other antibiotics． Exact measurement of MIC was impossible and relation between clinical results and
iMIC was not clarified． As to Serratia， MIC ranged between O．39 and 3．13 micrograms／ml which was
far superior to otlier antibiotics． Clinical response in this g’ roup was also excellent （rernarkable in 2
and good in 2）．
  8） Side eflfects were seen in JP patients， 2 of them being very sHght diarrhea． Liver function
was questionable in 5 cases， one of which quickly returned normal． ．AnYway， no serious untoward
effects were obseTved attribut，able to the medication of fosfomycin．
  4） NTone of the antibiotics oraliy a． dministered ever showed such a good effect for Pseudomonas
or Serratia infection， espicially for Serratia． Fosfomycin will be a powerfu1 weapon against hospital
acquired infe6tion， present and future．
は じ め に
 急性尿路感染症の起炎菌はE．coliがその大部分で
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Table 1． Cases treated by fosfomycin
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Table 2． Bacteriological effect
OrganismNumber of@Strains










































            時おり主訴を認め，
E’ coli・P「oteUS・Enterobacter， Pseudomonas geがそのたび
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Table 4． Laboratory finding















































































































































































































































































































































































































DK：B， GM， Cしの4種を選び， FOMと比較した．
なお，MIC測定方法は， FOMについてはFosfo－











































・×・ 1 Case No．2 40．25一．55．50
・X，’2 Ca＄e No．15 55一．60．55




















X・ S Case No，1 47．55．6D 一X5 Cc｝se Na13 105．47．ac
X，一2 Case No．5 55．47．80 ’X．’4 Case No．15 40－55．63
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